GSK launches pneumococcal vaccine

Synflorix is a polysaccharide conjugate vaccine indicated for active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae.

Synflorix is licensed for use in infants and children aged from 6 weeks to 2 years.

It offers protection against the same 7 serotypes of S. pneumoniae as Prevenar, plus three additional strains (1, 5 and 7F). These 10 serotypes are collectively thought to be responsible for 56–90% of cases of invasive pneumococcal disease in children aged under 5 years in Europe.

View Synflorix drug record

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more